David A. Siegel Unity Biotechnology, Inc. Transaction History

Two Sigma Advisers, LP

6 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q2 2022 Aug 15, 2022	SELL	$0.56 - $1.29 $70,840 - $163,185	-126,500 Reduced 37.66%	209,400 $118,000
Q1 2022 May 16, 2022	SELL	$0.72 - $1.86 $134,496 - $347,448	-186,800 Reduced 35.74%	335,900 $376,000
Q4 2021 Feb 14, 2022	BUY	$1.3 - $3.17 $477,750 - $1.16 Million	367,500 Added 236.79%	522,700 $763,000
Q3 2021 Nov 15, 2021	BUY	$2.91 - $4.5 $289,545 - $447,750	99,500 Added 178.64%	155,200 $466,000
Q2 2021 Aug 16, 2021	SELL	$4.15 - $6.3 $44,405 - $67,410	-10,700 Reduced 16.11%	55,700 $258,000
Q1 2021 May 17, 2021	BUY	$5.51 - $9.42 $365,864 - $625,488	66,400 New	66,400 $398,000

4.41M

Ticker UBX
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 14,036,200
Market Cap $16.1M
Description
Unity Biotechnology, Inc., a biotechnology company, engages in the research and development of therapeutics to slow, halt, or reverse diseases of aging. The company's lead drug candidate includes UBX1325, which is Phase II clinical trial for the treatment of age-related diseases of the eye, including diabetic macular edema, age-related macular d...

Get notified when there are updates to the investment portfolio of Two Sigma Advisers, LP, based on Form 13F filings with the SEC.

Stay updated on Two Sigma Advisers, LP and David A. Siegel with notifications on news.